Integration of National Health Insurance claims data and animal models reveals fexofenadine as a promising repurposed drug for Parkinson’s disease
Journal of Neuroinflammation · 2024
DOI: 10.1186/s12974-024-03041-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuroinflammation, 2024. Verfasst von Jae-Bong Kim und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Ajou University School of Medicine, 164, Worldcup-Ro, Yeongtong-Gu, Suwon, 16499, Korea. Hauptthemen laut MEDLINE: Parkinson Disease, Neurodegenerative Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Background
Parkinson’s disease (PD) is a common and costly progressive neurodegenerative disease of unclear etiology. A disease-modifying approach that can directly stop or slow its progression remains a major unmet need in the treatment of PD. A clinical pharmacology-based drug repositioning strategy is a useful approach for identifying new drugs for PD.
Methods
We analyzed claims data obtained from the National Health Insurance Service (NHIS), which covers a significant portion of the South Korean population, to investigate the association between antihistamines, a class of drugs commonly used to treat allergic symptoms by blocking H1 receptor, and PD in a real-world setting. Additionally, we validated this model using various animal models of PD such as the 6-hydroxydopmaine (6-OHDA), α-synuclein preformed fibrils (PFF) injection, and Caenorhabditis elegans ( C. elegans ) models. Finally, whole transcriptome data and Ingenuity Pathway Analysis (IPA) were used to elucidate drug mechanism pathways.
Results
We identified fexofenadine as the most promising candidate using National Health Insurance claims data in the real world. In several animal models, including the 6-OHDA, PFF injection, and C. elegans models, fexofenadine ameliorated PD-related pathologies. RNA-seq analysis and the subsequent experiments suggested that fexofenadine is effective in PD via inhibition of peripheral immune cell infiltration into the brain.
Conclusion
Fexofenadine shows promise for the treatment of PD, identified through clinical data and validated in diverse animal models. This combined clinical and preclinical approach offers valuable insights for developing novel PD therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Ajou University School of Medicine, 164, Worldcup-Ro, Yeongtong-Gu, Suwon, 16499, Korea.
- Center for Convergence Research of Neurological Disorders, Ajou University School of Medicine, Suwon, Korea.
- Neuroscience Graduate Program, Department of Biomedical Sciences, Ajou University School of Medicine, Suwon, Korea.
- Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Korea.
- Neuroscience Research Institute, Gachon University, Incheon, Korea.
- Standigm Inc., Seoul, Korea.
Förderung
- National Research Foundation of Korea
Zitieren
APA
Kim, J. B., Kim, Y., Kim, S. J., Ha, T. Y., Kim, D. K., Kim, D. W., So, M., Kim, S. H., Woo, H. G., Yoon, D., & Park, S. M. (2024). Integration of National Health Insurance claims data and animal models reveals fexofenadine as a promising repurposed drug for Parkinson’s disease. Journal of Neuroinflammation. https://doi.org/10.1186/s12974-024-03041-7
Vancouver
Kim JB, Kim Y, Kim SJ, Ha TY, Kim DK, Kim DW, et al. Integration of National Health Insurance claims data and animal models reveals fexofenadine as a promising repurposed drug for Parkinson’s disease. Journal of Neuroinflammation. 2024. doi:10.1186/s12974-024-03041-7
BibTeX
@article{Kim2024,
author = {Kim, Jae-Bong and Kim, Yujeong and Kim, Soo-Jeong and Ha, Tae-Young and Kim, Dong-Kyu and Kim, Dong Won and So, Minyoung and Kim, Seung Ho and Woo, Hyun Goo and Yoon, Dukyong and Park, Sang Myun},
title = {Integration of National Health Insurance claims data and animal models reveals fexofenadine as a promising repurposed drug for Parkinson’s disease},
journal = {Journal of Neuroinflammation},
year = {2024},
doi = {10.1186/s12974-024-03041-7}
}
EUVIMED